Product

REALQUALITY RQ-BCR-ABL p210 One-Step

REALQUALITY RQ-BCR-ABL p210 One-Step

REALQUALITY RQ-BCR-ABL p210 One-Step

Attributes

  • product-brand: AB ANALITICA

REALQUALITY RQ-BCR-ABL p210 One-Step Kit

The REALQUALITY RQ-BCR-ABL p210 One-Step kit is designed for the detection and quantification
of the t(9;22)(q34;q11) translocation, specifically the p210 transcript.
Using a one-step Real-Time RT-PCR method, the kit provides fast and accurate results for
monitoring Chronic Myeloid Leukemia (CML).

Key Features

  • Developed according to the Europe Against Cancer guidelines.
  • Includes a dUTP/UNG system to prevent PCR contamination.
  • Contains an internal fluorescent normalizer for reliable data output.
  • Requires only 5 μL of extracted RNA for each reaction.
  • When used with the RQ-BCR-ABL p210 Standard Kit, it allows precise MRD monitoring.
  • Shares a compatible thermal profile with other REALQUALITY leukemia kits (e.g., p190).
  • Validated on major Real-Time PCR instruments used in diagnostic laboratories.

Clinical Applications

  • Detection of the BCR-ABL p210 transcript.
  • Monitoring treatment response in CML patients.
  • Minimal Residual Disease (MRD) evaluation.

Kit Contents

  • Ready-to-use one-step Real-Time RT-PCR reagents.
  • Internal control to verify reaction performance.

About AB Analitica

AB Analitica is a leading Italian manufacturer of molecular diagnostic kits.
The company is known for its high-quality standards and innovative technologies.
Its products are widely used in hematology and oncology laboratories worldwide.

Exclusive Distributor in Iran

Fardad Azma Rad Co.
is the exclusive representative of AB Analitica in Iran.
The company provides guaranteed authenticity, specialized technical support,
and expert consultation for clinical and molecular laboratories.

Download Catalog

Additional Information:

The Philadelphia chromosome (Ph chromosome) is the hallmark cytogenetic abnormality identified in neoplastic diseases like Chronic Myeloid Leukemia (CML) and some cases of Acute Lymphoblastic Leukemia (ALL). It results from the translocation t(9;22)(q34;q11), present in over 95% of CML cases, and 5-10% of ALL cases in children and adults. At the molecular level, this translocation moves the ABL (c-ABL) gene from chromosome 9 to a specific region within the BCR gene on chromosome 22. The breakpoints in BCR can vary, forming different fusion transcripts. Most CML and Philadelphia-positive ALL cases involve the BCR-ABL p210 fusion protein, produced when the breakpoint occurs between exons 12 and 16 within the main cluster region (M-bcr) of BCR. This oncogenic fusion protein has kinase activity, leading to uncontrolled cell proliferation. A different breakpoint in BCR, mainly seen in ALL, produces BCR-ABL p190. Detection of these fusion transcripts through RNA extraction, reverse transcription, and PCR amplification provides valuable diagnostic and prognostic information, as well as disease monitoring via Minimal Residual Disease (MRD) assessment.

There are no reviews yet.

برای ثبت نظر خود، لطفا وارد سایت شوید.

Related products